Lariviks powder for solution for oral administration in bags No. 10

Name:
Lariviks. Release formPowder. INN Paracetamol + guaifenesin + phenylephrine. FTGS Means for eliminating the symptoms of acute respiratory infections and the ‘cold’ (non-narcotic analgesic + antitussive + antiallergic agent).
Description:
Powder from white to white with a yellowish tint, with a smell of lemon and menthol. The presence of soft lumps, blotches of white and yellow is allowed. Composition One package contains: active substances: paracetamol – 325 mg, guaifenesin – 200 mg, phenylephrine hydrochloride – 10 mg; excipients: tartaric acid, anhydrous citric acid, sodium citrate, aspartame, anhydrous colloidal silicon dioxide, lemon lime flavor, menthol flavor, sugar. Pharmacotherapeutic group Other analgesics-antipyretics. ATC code: M2BE51 Pharmacological action Combined drug, the action of which is due to its constituent components. Paracetamol has an analgesic, antipyretic and weak anti-inflammatory effect. The mechanism of action is associated with inhibition of prostaglandin synthesis and influence on the thermoregulatory center in the hypothalamus. Guaifenesin has an expectorant effect. Guaifenesin stimulates gastric mucosal receptors, which, in turn, initiate reflex secretion of respiratory fluid, which leads to an increase in volume and a decrease in the viscosity of bronchial secretions and contributes to the transition of an unproductive cough into a productive one. Phenylephrine is a sympathomimetic, has a pronounced alpha-adrenergic activity, constricts the vessels of the nasal mucosa, eliminates swelling and hyperemia of the nasal mucosa. Indications for use Short-term relief of symptoms of acute respiratory diseases, accompanied by chills, fever, headache and muscle 60, nasal congestion and cough with difficult discharge of viscous sputum. Method of application and dosage Dissolve the contents or 2 packets in a glass of hot, but not boiling water (250 ml). Allow to cool to an acceptable temperature and drink. Adults and children over 12 years of age take 1 to 2 packets every 8-12 hours. Do not take more than 4 packets per day. The maximum duration of treatment without consulting a doctor is 3 days (when taken as an antipyretic) and no more than 5 days (as an anesthetic). Side effect The frequency of development of adverse reactions is given in the following gradation: very often (≥1 / 10); often (≥l/100, <1/10); infrequently (≥1/1000, 4/100); rarely (≥1/10000, 4/1000); very rarely (<1/10000); frequency unknown (cannot be estimated from available data). Paracetamol The frequency of these reactions has not been determined, but usually they occur rarely. Blood and lymphatic system disorders: thrombocytopenia, agranulocytosis; Immune system disorders: anaphylactic reactions, skin hypersensitivity reactions, including skin rash, Quincke's edema and Stevens-Johnson syndrome; Respiratory, thoracic and mediastinal disorders: bronchospasm in patients sensitive to aspirin and other NSAIDs; Gastrointestinal disorders: acute pancreatitis; Hepatic and biliary tract disorders: liver dysfunction, guaifenesin The frequency of these reactions has not been determined, but they are usually rare. Immune system disorders: allergic reactions, angioedema, anaphylactic reactions; Respiratory, thoracic and mediastinal disorders: dyspnoea (shortness of breath has been reported in association with other symptoms of hypersensitivity); Gastrointestinal disorders: nausea, vomiting, discomfort in the gastrointestinal tract; Skin and subcutaneous tissue disorders: rash, urticaria. Phenylephrine The following adverse events have been observed in clinical trials with phenylephrine and are therefore the most commonly reported. Mental disorders: nervousness, irritability, restlessness and excitability; Nervous system disorders: headache, dizziness, insomnia; Vascular disorders: increased blood pressure; Gastrointestinal disorders: nausea, vomiting, diarrhea; Adverse events identified during post-marketing use are listed below. The frequency of these events is unknown, but they are likely to be very rare. On the part of the organ of vision: mydriasis, acute angle-closure glaucoma (most likely in people with angle-closure glaucoma); Cardiac disorders: tachycardia, palpitations; Skin and subcutaneous tissue disorders: allergic reactions (eg, rash, urticaria, allergic dermatitis, including cross-sensitivity with other sympathomimetics); Renal and urinary disorders: dysuria, urinary retention. This is most likely in individuals with bladder outlet obstruction such as prostatic hypertrophy. Contraindications Hypersensitivity to individual components of the drug; liver dysfunction and severe chronic renal failure; arterial hypertension; ischemic heart disease (acute myocardial infarction, atherosclerosis of the coronary arteries); aortic stenosis; tachyarrhythmia; hyperthyroidism; alcoholism; diabetes; simultaneous use of beta-blockers, tricyclic antidepressants, monoamine oxidase inhibitors (including within 14 days after their withdrawal), paracetamol-containing agents and sympathomimetic decongestants; peptic ulcer of the stomach and duodenum in the acute stage; prostatic hyperplasia; angle-closure glaucoma; pheochromocytoma; children's age up to 12 years; age over 65; pregnancy and lactation, Precautions: glucose-β-phosphate dehydrogenase deficiency, blood diseases, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson, Rotor syndromes), vasospastic diseases (Raynaud's syndrome), hyperoxaluria, bronchial asthma, COPD (chronic obstructive pulmonary disease) . Overdose Usually associated with an overdose of paracetamol, to a lesser extent with an overdose of phenylephrine hydrochloride and guaifenesin. If you suspect an overdose of the drug, you should immediately call a doctor, even if the condition has not worsened, symptoms of poisoning may appear later. Symptoms: pallor of the skin, nausea, vomiting, loss of appetite and pain in the abdomen, increased blood pressure, decreased heart rate and arrhythmia. Treatment: Provide emergency medical care (in a hospital). Within the first hour after an overdose, introduce activated charcoal, perform a gastric lavage and, regardless of the amount of the drug taken, but no later than 8-16 hours after the overdose, introduce an antidote without waiting for the results of a blood test. Antidotes are acetylcysteine and methionine. For high blood pressure, alpha receptor antagonists (eg, phentolamine, intravenously) are used. Precautions Seek medical attention if symptoms: do not improve within 5 days; accompanied by a fever that lasts more than 3 days; include a sore throat that does not go away for more than 3 days, accompanied by fever, headache, rash, nausea or vomiting. Patients suffering from chronic cough or asthma should consult a doctor before taking the drug. Patients should stop using the drug and consult a doctor if the cough lasts more than 5 days or returns, or is accompanied by fever, rash or persistent headache. It should not be taken concomitantly with drugs that depress the cough reflex. Great care should be taken in patients with angina pectoris. Sympathomimetic drugs can act as brain stimulants, causing insomnia, nervousness, hyperpyrexia, tremors, and epileptiform seizures. Simultaneous use with other sympathomimetic drugs (decongestants, appetite suppressants, amphetamine-type psychostimulants) should be avoided. The simultaneous use of other medicinal products containing paracetamol should be avoided. Larivix distorts the results of laboratory tests of glucose and uric acid in blood plasma. One sachet contains 1 17.3 mg of sodium, which should be taken into account in patients on a low sodium diet. Lavirax contains aspartame, which is a source of phenylalanine, which is toxic to patients with phenylketonuria. Due to the presence of sugar, it is not recommended for patients with rare congenital fructose intolerance, glucose-galactose malabsorption and sucrase / isomaltase deficiency. Use in Pediatrics This drug is contraindicated for children under 12 years of age. Use during pregnancy and lactation. The drug is contraindicated during pregnancy and lactation. Influence on the ability to drive vehicles and other potentially dangerous mechanisms Lariviks can cause dizziness, confusion, so during treatment it is not recommended to drive a car and engage in other potentially hazardous activities. Interaction with other drugsParacetamol The rate of absorption of paracetamol increases when taken with drugs that increase gastric emptying (for example, metoclopramide or domperidone). Cholestyramine reduces the absorption of paracetamol if given within an hour before or after taking paracetamol. The anticoagulant effect of coumarins (including warfarin) may be enhanced by prolonged daily use of drugs containing paracetamol, which may lead to an increased risk of bleeding. It may be necessary to reduce the dose of anticoagulants if treatment with drugs containing paracetamol is necessary. Potentially hepatotoxic drugs or agents that cause induction of microsomal liver enzymes (eg, alcohol, barbiturates, monoamine oxidase inhibitors, and tricyclic antidepressants) may increase the hepatotoxicity of paracetamol, especially when overdosed. The simultaneous use of zidovudine and paracetamol increases the risk of neutropenia. Acetylsalicylic acid increases the half-life of paracetamol. Simultaneous use of paracetamol with NSAIDs may increase their nephrotoxicity. Guaifenesin During the first days after taking the drug, the results of the determination of 5-hydroxyindoleacetic acid and vinyl mandelic acid in the urine by the colorimetric method may be distorted. Guaifenesin enhances the effect of sedatives and muscle relaxants. Phenylephrine Concomitant use of phenylephrine with monoaminoxylase inhibitors can lead to the development of a hypertensive crisis. The simultaneous use of phenylephrine with other sympathomimetic amines may increase the risk of side effects from the cardiovascular system. Phenylephrine may reduce the effectiveness of beta-blockers and other antihypertensive drugs (eg, debrisoquine, guanethidine, reserpine, methyldopa), leading to an increased risk of developing hypertension and other adverse events from the cardiovascular system. Tricyclic antidepressants (eg, amitriptyline) increase the risk of phenylephrine adverse events from the cardiovascular system. Phenothiazides, used as a sedative, increase adverse effects from the central nervous system. Ergot alkaloids (ergotamine and methylseride) increase the risk of ergotism. Digoxin and cardiac glycosides increase the risk of irregular heartbeat and heart attack. Inhalation anesthetics (including chloroform, enflurane, halothane, isoflurane) increase the risk of severe atrial and ventricular arrhythmias. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 °C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiry date stated on the package. Packing 4.36 g of powder in bags of multilayer packaging material (polyethylene terephthalate film/polypropylene film/aluminum foil/polyethylene film). 5 or 10 packs along with instructions for medical use in a pack of cardboard. Terms of dispensing from pharmacies Without a doctor's prescription. Buy Lariviks powder for oral solution in bags No. 10 Price for Larivix powder for oral solution in bags No. 10 Instructions for use for Larivix powder for oral solution in bags No. 10